HK Stock Market Move | Pharmaceutical stocks generally declined, with CRO concept stocks leading the losses. GENSCRIPT BIO (01548) once fell more than 18%.

Pharmaceutical stocks generally declined, with CRO concept stocks leading the losses. As of press time, GENSCRIPT BIO (01548) fell 16.04% to HK$35.38; Pharmaron Beijing (03759) fell 7.86% to HK$28.14; Hangzhou Tigermed Consulting (03347) fell 6.93% to HK$41.92; REMEGEN (09995) fell 4.55% to HK$67.1. On the news front, Hong Kong innovative drug stocks, as rate-sensitive assets, have seen their performance affected by the Federal Reserve's movements. Cleveland Fed President Hammack said that smaller, more frequent monetary policy adjustments would help keep inflation expectations stable, and would be better than waiting now and risking the need for larger policy corrections later. From October 6 to October 12, U.S. AI pharmaceutical company Twist retreated more than 25% after hitting a high. Industrial believes that while short-term disturbances stem from periodic pullbacks in comparable U.S. companies, the long-term industrial trend of AI4S still has potential. The firm said that demand for AI4S will increase significantly in 2026, related investment and financing will remain active, upstream gene and protein synthesis suppliers will see rapid growth in orders and performance, and incremental demand is expected to extend downstream.